# Schrodinger, Inc. (SDGR) Stock Analysis: Exploring the 86% Potential Upside and Analyst Confidence

- Link: https://www.directorstalkinterviews.com/schrodinger-inc-sdgr-stock-analysis-exploring-the-86-potential-upside-and-analyst-confidence/4121245036
- Published: 2026-03-17T11:25:21+00:00
- Author: Madison Wilson

Schrodinger, Inc. (NASDAQ: SDGR), a pivotal player in the healthcare sector, particularly
within the health information services industry, is capturing attention with its
innovative approach to drug development and materials applications. With its headquarters
in New York and a global footprint spanning the United States, Asia-Pacific, Europe,
the Middle East, and Africa, Schrodinger is leveraging its cutting-edge physics-
based computational platform to spearhead advancements in molecular discovery.

Currently trading at $12.70, Schrodinger’s stock has seen a modest price increase
of 0.02%. However, it’s the potential upside that is turning heads among investors.
With a target price range of $18.00 to $32.00 and an average target of $23.67, the
stock presents a staggering potential upside of 86.35%. This optimism is bolstered
by the fact that the company has received seven buy ratings and only two hold ratings
from analysts, with no sell ratings in sight.

Despite these promising ratings, Schrodinger’s financial metrics reveal challenges
that investors should consider. The company’s revenue growth has dipped by 1.20%,
and with an EPS of -1.41, Schrodinger is navigating through a period of unprofitability.
The return on equity stands at -26.29%, reflecting further on the company’s current
inability to generate profits from shareholders’ equity. These figures suggest Schrodinger
is still in a growth and development phase, typical of companies investing heavily
in research and development to drive future gains.

On the technical front, Schrodinger’s 50-day moving average is $14.19, while its
200-day moving average is $18.47, indicating that the stock is trading below both
averages, a signal that might concern some investors. Additionally, the RSI (14)
is at 20.56, which falls into the oversold territory, potentially signaling a buying
opportunity for those bullish on the company’s long-term prospects.

Schrodinger’s strategic collaborations could be a critical factor in its future 
success. The company has a noteworthy research collaboration and license agreement
with Novartis Pharma AG, aiming to advance multiple development candidates. Such
partnerships are pivotal for the Drug Discovery segment, which focuses on building
a robust portfolio of preclinical and clinical programs.

While the company does not currently pay dividends, its free cash flow stands at
approximately $99.98 million, a reassuring figure indicating that Schrodinger has
the cash available to sustain its operations and continue investing in its innovative
platforms.

For investors seeking exposure to the healthcare sector’s cutting-edge technology
and potential high-reward opportunities, Schrodinger offers a compelling proposition.
The significant potential upside, coupled with strong analyst ratings, may be an
attractive scenario for long-term investors willing to weather the inherent risks
associated with an emerging technology-driven company. As Schrodinger continues 
to advance its computational platforms and expand its collaborative efforts, keeping
a close eye on its financial health and strategic developments will be essential
for discerning investors.

Share on:
